Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04569799 · ClinicalTrials.gov registry record · Phase 4
Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE
A Phase 4 study, sponsored by Milton S. Hershey Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
NCT04569799 is a Phase 4 study that has completed, run by Milton S. Hershey Medical Center. The registered enrollment target is 26 participants.
The verdict
NCT04569799, a Phase 4 study, has completed, sponsored by Milton S. Hershey Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC) after receiving TACE treatment
Interventions
- DRUG Lumason
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2020-10-14 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04569799
The ClinicalTrials.gov registry entry for NCT04569799 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Milton S. Hershey Medical Center, which has 396 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lumason is the first listed.
NCT04569799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04569799 about?
NCT04569799 is a clinical study titled "Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post TACE". The purpose of this research study is to find out if a different type of imaging study called contrast enhanced ultrasound (CEUS) is as good as, or better than CT or MRI in patients diagnosed with hepatocellular carcinoma (HCC) after receiving TACE treatment
What is the current status of trial NCT04569799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2020-10-14. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT04569799?
The interventions under investigation include: Lumason (DRUG).
Who is sponsoring clinical trial NCT04569799?
This trial is sponsored by Milton S. Hershey Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.